Healthy Activities for Prize Incentives

NCT00717444 | Completed

• 2 other identifiers: 08-251-21R01DA022739-01A2
• Study Type: interventional
• Target: 75
• Locations: 1 country
• Sites: 1

Brief Summary

In this Stage 1 therapy development project, we plan to develop, formalize, and derive effect size estimates of a contingency management (CM) therapy that focuses on improving health, especially as related to increasing low intensity physical activities, such as walking, resistance training, and stretching. The Healthy Activities for Prize Incentives (HAPI) intervention will be targeted toward and tested within HIV-positive substance abusers who attend HIV drop-in centers. After initial therapy development in a Stage 1a pilot project with 9 patients, the therapy manuals and materials will be adapted and refined. In a Stage 1b controlled trial, we will recruit and randomize 70 substance abusing HIV-positive patients to (a) HAPI plus 12-step facilitation therapy or (b) contingency management for abstinence plus 12-step facilitation therapy. Each intervention will consist of one weekly individual therapy session for 16 weeks. All participants will provide urine and breath specimens twice weekly that will be tested for opioids, cocaine, methamphetamine, marijuana and alcohol. Patients in both conditions will earn the chance to win prizes for submitting drug-negative specimens, and those randomized to the HAPI condition will also earn the chance to win prizes for engaging in healthy activities. Physical activity levels, drug use, psychological symptoms, and subjective and objective indicators of health (body mass index, waist circumference, blood pressure, viral load) will be measured pre-treatment and at months 2 and 4 (post-treatment), as well as at a 7-month (3 months after treatment) follow-up evaluation. Compared to those receiving 12-step facilitation with contingency management for abstinence, we expect that those in the HAPI condition will participate in more physical activities, decrease drug use to a greater extent, evidence reduced depression, and show trends toward improvements in health indices. If effect sizes in at least the small to medium range are noted across all domains, we will consider the therapy appropriate for further evaluation in a Stage 2 therapy development study.

Conditions

Substance Abuse; HIV Infections

Keywords

Substance Abuse; HIV; Contingency Management; Physical Activity

Outcome Measures

Primary Outcomes (1)

• drug use

  baseline and each follow-up

Secondary Outcomes (3)

• physical activity

  baseline and each follow-up

• psychological symptoms

  baseline and each follow-up

• medical outcomes

  baseline and each follow-up

Study Arms (2)

1

EXPERIMENTAL

contingency management for abstinence plus 12-step facilitation therapy and contingency management for completing healthy activities

Behavioral: contingency management

2

EXPERIMENTAL

contingency management for abstinence plus 12-step facilitation therapy

Behavioral: contingency management

Interventions

contingency management BEHAVIORAL

contingency management for abstinence plus 12-step facilitation therapy prizes awarded for target behaviors

2

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• HIV+ and a member of Connections
• Age 18-65 years
• English speaking
• Past-year DSM-IV diagnosis of opioid, cocaine, methamphetamine, alcohol, or marijuana abuse or dependence
• Written permission from one's primary care or infectious disease physician to participate in the study and an exercise program
• Plans to reside in the local area for the next 8 months and
• Willing to sign informed consent

You may not qualify if:

• Inability to comprehend the study as assessed by the Informed Consent Quiz and Mini-Mental Status Exam (MMSE)
• Severely disruptive behavior
• In recovery for pathological gambling (due to potential similarity between the contingency management procedure and gambling)
• Serious uncontrolled psychiatric disorder other than substance use disorders that require inpatient hospitalization (e.g., active bipolar disorder, psychosis, suicidal)
• History of myocardial infarction, stroke, unstable angina, coronary artery bypass grafting, angioplasty/stent, uncontrolled arrhythmia, or hyperthyroidism in the past 6 months as reported by patient or physician
• Blood pressure \>165/95 mmHg and
• Grossly abnormal findings on indices of physical functioning (\>2 SDs above means for sedentary age/gender norms according to ACSM, 2006)
• Pregnancy

Sponsors & Collaborators

• UConn Health: lead
• National Institute on Drug Abuse (NIDA): collaborator

Study Sites (1)

Connections, Inc.

Hartford, Connecticut, 06106, United States

Location

MeSH Terms

Conditions

Substance-Related Disorders; HIV Infections; Motor Activity

Condition Hierarchy (Ancestors)

Chemically-Induced Disorders; Mental Disorders; Blood-Borne Infections; Communicable Diseases; Infections; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; RNA Virus Infections; Virus Diseases; Genital Diseases; Urogenital Diseases; Immunologic Deficiency Syndromes; Immune System Diseases; Behavior

Study Officials

• Nancy M Petry, Ph.D.

  UConn Health

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: FACTORIAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 15, 2008
• First Posted: July 17, 2008
• Study Start: September 1, 2008
• Primary Completion: May 1, 2013
• Study Completion: May 1, 2013
• Last Updated: December 26, 2018

Record last verified: 2018-12

Locations

US (1)